Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-06, Stock:NVS, The news for the past five days is as follows:
2018-03-29: NEWS1: Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster.NEWS2: Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster.NEWS3: What’s Merck’s Valuation in March 2018?.NEWS4: What’s Merck’s Valuation in March 2018?.NEWS5: Exclusive: Penn patient shares the story of her CAR-T cell therapy journey.NEWS6: Exclusive: Penn patient shares the story of her CAR-T cell therapy journey.NEWS7: How Is Novartis’s Cosentyx Positioned after 4Q17?.NEWS8: How Novartis’s Ophthalmology Business Performed in 2017.NEWS9: How Novartis’s Ophthalmology Business Performed in 2017.NEWS10: The Swiss Stock Market Fell On Pharma Weakness.NEWS11: The Swiss Stock Market Fell On Pharma Weakness.NEWS12: How Merck Stock Has Performed Recently.NEWS13: How Merck Stock Has Performed Recently.NEWS14: How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?.NEWS15: How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?.
2018-04-02: NEWS1: Puma's Shares Fall This Year Post a Solid 2017: Here's Why.NEWS2: Puma's Shares Fall This Year Post a Solid 2017: Here's Why.NEWS3: On World Autism Awareness Day, A Look At Biotech Firms With Potential Treatments In The Pipeline.NEWS4: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS5: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS6: VEA, EFU: Big ETF Inflows.NEWS7: VEA, EFU: Big ETF Inflows.NEWS8: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS9: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS10: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS11: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS12: How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed.NEWS13: How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed.NEWS14: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.NEWS15: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.
2018-04-03: NEWS1: CASI Makes Case For Hope, MYND On Track, URGN Sprints, No Stopping INNT.NEWS2: CASI Makes Case For Hope, MYND On Track, URGN Sprints, No Stopping INNT.NEWS3: Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs.NEWS4: Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs.NEWS5: Why GlaxoSmithKline Stock Rose in the Week Ended March 29.NEWS6: Why GlaxoSmithKline Stock Rose in the Week Ended March 29.NEWS7: Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label.NEWS8: Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label.NEWS9: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS10: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS11: The Swiss Stock Market Begins The Week With A Substantial Loss.NEWS12: The Swiss Stock Market Begins The Week With A Substantial Loss.NEWS13: What Analysts Recommend for Novartis in March 2018.NEWS14: What Analysts Recommend for Novartis in March 2018.NEWS15: Will These Drugs Reach Blockbuster Status?.NEWS16: Will These Drugs Reach Blockbuster Status?.
2018-04-04: NEWS1: Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug.NEWS2: Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug.NEWS3: GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?.NEWS4: GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?.NEWS5: Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale.NEWS6: Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale.NEWS7: Johnson & Johnson’s Quarterly Revenue Trend in 2017.NEWS8: Today’s Research Reports on Stocks to Watch: UroGen Pharma and Novartis.NEWS9: Novartis Announces JAMA Cardiology Publication Of Data.NEWS10: Novartis Announces JAMA Cardiology Publication Of Data.
2018-04-05: NEWS1: U.S. Medicare sets outpatient rate for Yescarta reimbursement.NEWS2: 8 Biotech Stocks With Clinical Trial Outcomes In April.NEWS3: Conatus' Emricasan Fails in Phase II Study, Shares Sink.NEWS4: Conatus' Emricasan Fails in Phase II Study, Shares Sink.NEWS5: Novartis Announces Data on Cardiovascular Drug Entresto.NEWS6: Novartis Announces Data on Cardiovascular Drug Entresto.NEWS7: Novartis Announces Data on Cardiovascular Drug Entresto.NEWS8: 3 Emerging Technologies Set to Transform the Pharma World.NEWS9: 3 Emerging Technologies Set to Transform the Pharma World.NEWS10: The Swiss Stock Market Jumped As Global Trade Concerns Relax.NEWS11: The Swiss Stock Market Jumped As Global Trade Concerns Relax.

Answer: Decrease